Doxorubicin only causes clinically significant damage to the heart of a small percentage of cancer patients, but it causes clinically significant damage to the cardiovascular system of most patients. This is what the VO2peak data has revealed. This is important as it is damage to the cardiovascular system that matters to the patients and their quality of life.
We are still pursuing the orphan drug opportunity via AML, but more as an insurance policy if CPACS fails for some unexpected reason. Developing for an orphan indication is not usually any faster than for a non-orphan indications as trial recruitment is often the limiting factor.
Yes the market potential numbers are hard to believe, but so far nobody has been able to come with a plausible reason why they are wrong. If you wanted to be useful try to find where exactly Triangle went wrong in their modelling.
RAC Price at posting:
$1.89 Sentiment: Buy Disclosure: Held
(20min delay)